Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: Effect on natural cytotoxicity

K. G. M. Park, S. D. Heys, J. B. Murray, P. D. Hayes, J. A. Ashby, C. R. Franks, O. Eremin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Natural cytotoxicity (natural killer, NK, and lymphokine-activated killer, LAK, activity) was documented in 12 patients with metastatic colorectal cancer, both before and after a 5-day course of continuous therapy with intravenous recombinant interleukin-2 (rIL-2). Treatment induced a substantial increase in circulating CD56+ lymphocytes (pretreatment: 12.1±6.9%, mean ± SD; posttreatment: 39.2±6.9%. Maximal NK cell activity was induced by treatment with rIL-2 but only suboptimal augmentation of LAK cell cytotoxicity was obtained. This study indicates that although continuous infusion of rIL-2 does have a significant effect on natural cytotoxicity, this is suboptimal and further studies are necessary to define the most efficacious immunity-enhancing regimens of therapy, thereby hopefully improving clinical outcome of rIL-2 treatment.

Original languageEnglish
Pages (from-to)53-58
Number of pages6
JournalCancer Immunology Immunotherapy
Volume35
Issue number1
DOIs
Publication statusPublished - Jan 1992

Fingerprint

Interleukin-2
Colorectal Neoplasms
Therapeutics
Lymphokine-Activated Killer Cells
Lymphokines
Natural Killer Cells
Immunity
Lymphocytes

Keywords

  • Colorectal cancer
  • Cytotoxicity
  • Interleukin-2
  • Natural cytotoxicity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Park, K. G. M., Heys, S. D., Murray, J. B., Hayes, P. D., Ashby, J. A., Franks, C. R., & Eremin, O. (1992). Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: Effect on natural cytotoxicity. Cancer Immunology Immunotherapy, 35(1), 53-58. https://doi.org/10.1007/BF01741055

Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer : Effect on natural cytotoxicity. / Park, K. G. M.; Heys, S. D.; Murray, J. B.; Hayes, P. D.; Ashby, J. A.; Franks, C. R.; Eremin, O.

In: Cancer Immunology Immunotherapy, Vol. 35, No. 1, 01.1992, p. 53-58.

Research output: Contribution to journalArticle

Park, K. G. M. ; Heys, S. D. ; Murray, J. B. ; Hayes, P. D. ; Ashby, J. A. ; Franks, C. R. ; Eremin, O. / Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer : Effect on natural cytotoxicity. In: Cancer Immunology Immunotherapy. 1992 ; Vol. 35, No. 1. pp. 53-58.
@article{a823af04e0d4454fbbd15b96b866a750,
title = "Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: Effect on natural cytotoxicity",
abstract = "Natural cytotoxicity (natural killer, NK, and lymphokine-activated killer, LAK, activity) was documented in 12 patients with metastatic colorectal cancer, both before and after a 5-day course of continuous therapy with intravenous recombinant interleukin-2 (rIL-2). Treatment induced a substantial increase in circulating CD56+ lymphocytes (pretreatment: 12.1±6.9{\%}, mean ± SD; posttreatment: 39.2±6.9{\%}. Maximal NK cell activity was induced by treatment with rIL-2 but only suboptimal augmentation of LAK cell cytotoxicity was obtained. This study indicates that although continuous infusion of rIL-2 does have a significant effect on natural cytotoxicity, this is suboptimal and further studies are necessary to define the most efficacious immunity-enhancing regimens of therapy, thereby hopefully improving clinical outcome of rIL-2 treatment.",
keywords = "Colorectal cancer, Cytotoxicity, Interleukin-2, Natural cytotoxicity",
author = "Park, {K. G. M.} and Heys, {S. D.} and Murray, {J. B.} and Hayes, {P. D.} and Ashby, {J. A.} and Franks, {C. R.} and O. Eremin",
year = "1992",
month = "1",
doi = "10.1007/BF01741055",
language = "English",
volume = "35",
pages = "53--58",
journal = "Cancer Immunology Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer

T2 - Effect on natural cytotoxicity

AU - Park, K. G. M.

AU - Heys, S. D.

AU - Murray, J. B.

AU - Hayes, P. D.

AU - Ashby, J. A.

AU - Franks, C. R.

AU - Eremin, O.

PY - 1992/1

Y1 - 1992/1

N2 - Natural cytotoxicity (natural killer, NK, and lymphokine-activated killer, LAK, activity) was documented in 12 patients with metastatic colorectal cancer, both before and after a 5-day course of continuous therapy with intravenous recombinant interleukin-2 (rIL-2). Treatment induced a substantial increase in circulating CD56+ lymphocytes (pretreatment: 12.1±6.9%, mean ± SD; posttreatment: 39.2±6.9%. Maximal NK cell activity was induced by treatment with rIL-2 but only suboptimal augmentation of LAK cell cytotoxicity was obtained. This study indicates that although continuous infusion of rIL-2 does have a significant effect on natural cytotoxicity, this is suboptimal and further studies are necessary to define the most efficacious immunity-enhancing regimens of therapy, thereby hopefully improving clinical outcome of rIL-2 treatment.

AB - Natural cytotoxicity (natural killer, NK, and lymphokine-activated killer, LAK, activity) was documented in 12 patients with metastatic colorectal cancer, both before and after a 5-day course of continuous therapy with intravenous recombinant interleukin-2 (rIL-2). Treatment induced a substantial increase in circulating CD56+ lymphocytes (pretreatment: 12.1±6.9%, mean ± SD; posttreatment: 39.2±6.9%. Maximal NK cell activity was induced by treatment with rIL-2 but only suboptimal augmentation of LAK cell cytotoxicity was obtained. This study indicates that although continuous infusion of rIL-2 does have a significant effect on natural cytotoxicity, this is suboptimal and further studies are necessary to define the most efficacious immunity-enhancing regimens of therapy, thereby hopefully improving clinical outcome of rIL-2 treatment.

KW - Colorectal cancer

KW - Cytotoxicity

KW - Interleukin-2

KW - Natural cytotoxicity

UR - http://www.scopus.com/inward/record.url?scp=0026532440&partnerID=8YFLogxK

U2 - 10.1007/BF01741055

DO - 10.1007/BF01741055

M3 - Article

C2 - 1611623

AN - SCOPUS:0026532440

VL - 35

SP - 53

EP - 58

JO - Cancer Immunology Immunotherapy

JF - Cancer Immunology Immunotherapy

SN - 0340-7004

IS - 1

ER -